Total Funding
23
39
Total FundingVenture - Series Unknown raised
Growth Score
-3 pts
Heat Score
-7 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
67547
Cernostics is a life science company developing new molecular diagnostic tests to treat cancer.
Acquired by 
Castle Biosciences
Mike Hoerres: Chief Executive OfficerPast Role: Geisinger, Principal, Office of Strategic Industry Partnerships
Rebecca Critchley-Thorne: Chief Scientific OfficerPast Role: Stanford University, Post doc
About the Company
Cernostics is a life science company developing new molecular diagnostic tests for the fight against cancer. Most current diagnostic approaches offer a limited view of cancer because they fail to evaluate the tumor as a system composed of multiple cell types, not merely tumor cells.
Its patent-protected technology platform, TissueCypher, uniquely
analyzes whole slide digital images with multiplexed fluorescence, providing greater information and accuracy than traditional subjective tissue diagnostics.
Women Founded
